Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
26 Oct 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
21 Feb 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
Current reports
8-K
Results of Operations and Financial Condition
29 Feb 24
8-K
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
25 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Results of Operations and Financial Condition
26 Oct 23
8-K
Termination of a Material Definitive Agreement
19 Oct 23
8-K
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
19 Oct 23
8-K
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
28 Sep 23
8-K
Other Events
22 Sep 23
8-K
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
15 Sep 23
8-K
Results of Operations and Financial Condition
3 Aug 23
Registration and prospectus
POSASR
Automatic shelf registration (post-effective amendment)
7 Nov 23
D
$35.90 mm in equity / Common Stock, sold $35.90 mm, 40 investors
8 May 23
S-3ASR
Automatic shelf registration
5 May 23
POSASR
Automatic shelf registration (post-effective amendment)
28 Apr 23
S-8
Registration of securities for employees
16 Dec 22
S-3ASR
Automatic shelf registration
16 Dec 22
S-8
Registration of securities for employees
23 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Apr 22
S-8
Registration of securities for employees
5 Jan 22
POSASR
Automatic shelf registration (post-effective amendment)
7 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
PRE 14A
Preliminary proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
28 May 20
DEFA14A
Additional proxy soliciting materials
27 Apr 20
Other
UPLOAD
Letter from SEC
27 Oct 21
CORRESP
Correspondence with SEC
19 Oct 21
CT ORDER
Confidential treatment order
19 Oct 21
UPLOAD
Letter from SEC
6 Oct 21
CORRESP
Correspondence with SEC
23 Sep 21
UPLOAD
Letter from SEC
26 Aug 21
CT ORDER
Confidential treatment order
17 Sep 20
CT ORDER
Confidential treatment order
15 Jul 20
SEC STAFF
SEC staff action: Order
18 Feb 20
SEC STAFF
SEC staff action: Order
7 Feb 20
Ownership